Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study per
Sponsor: Icahn School of Medicine at Mount Sinai
Check if you qualify for this myelofibrosis clinical trial in New York, NY
If you're searching for myelofibrosis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.